95 research outputs found
Smoking Patterns and Receipt of Cessation Services Among Pregnant Women in Argentina and Uruguay
Introduction: The 5Aâs (Ask, Advise, Assess, Assist, and Arrange) strategy, a best-practice approach for cessation counseling, has been widely implemented in high-income countries for pregnant women; however, no studies have evaluated implementation in middle-income countries. The study objectives were to assess smoking patterns and receipt of 5Aâs among pregnant women in Buenos Aires, Argentina and Montevideo, Uruguay. Methods: Data were collected through administered questionnaires to women at delivery hospitalizations during October 2011âMay 2012. Eligible women attended one of 12 maternity hospitals or 21 associated prenatal care clinics. The questionnaire included demographic data, tobacco use/cessation behaviors, and receipt of the 5Aâs. Self-reported cessation was verified with saliva cotinine. Results: Overall, of 3400 pregnant women, 32.8% smoked at the beginning of pregnancy; 11.9% quit upon learning they were pregnant or later during pregnancy, and 20.9% smoked throughout pregnancy. Smoking prevalence varied by country with 16.1% and 26.7% who smoked throughout pregnancy in Argentina and Uruguay, respectively. Among pregnant smokers in Argentina, 23.8% reported that a provider asked them about smoking at more than one prenatal care visit; 18.5% were advised to quit; 5.3% were assessed for readiness to quit, 4.7% were provided assistance, and 0.7% reported follow-up was arranged. In Uruguay, those percentages were 36.3%, 27.9%, 5.4%, 5.6%, and 0.2%, respectively. Conclusions: Approximately, one in six pregnant women smoked throughout pregnancy in Buenos Aires and one in four in Montevideo. However, a low percentage of smokers received any cessation assistance in both countries. Healthcare providers are not fully implementing the recommended 5Aâs intervention to help pregnant women quit smoking.Fil: Berrueta, Amanda Mabel. Instituto de Efectividad ClĂnica y Sanitaria; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Morello, Paola. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: AlemĂĄn, Alicia. Unidad de InvestigaciĂłn ClĂnica y EpidemiolĂłgica Montevideo; UruguayFil: Tong, Van T.. Centers for Disease Control and Prevention; Estados UnidosFil: Johnson, Carolyn. Tulane School of Public Health and Tropical Medicine; Estados UnidosFil: Dietz, Patricia M.. Centers for Disease Control and Prevention; Estados UnidosFil: Farr, Sherry L.. Centers for Disease Control and Prevention; Estados UnidosFil: Mazzoni, Agustina. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Colomar, Mercedes. Unidad de InvestigaciĂłn ClĂnica y EpidemiolĂłgica Montevideo; UruguayFil: Ciganda, Alvaro. Unidad de InvestigaciĂłn ClĂnica y EpidemiolĂłgica Montevideo; UruguayFil: Llambi, Laura. Unidad de InvestigaciĂłn ClĂnica y EpidemiolĂłgica Montevideo; UruguayFil: BecĂș, Ana. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Gibbons, Luz. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Smith, Ruben A.. Centers for Disease Control and Prevention; Estados UnidosFil: Buekens, Pierre. Tulane School of Public Health and Tropical Medicine; Estados UnidosFil: Belizan, Jose. Instituto de Efectividad ClĂnica y Sanitaria; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Althabe, Fernando. Instituto de Efectividad ClĂnica y Sanitaria; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentin
Meta-analysis of global livestock urine-derived nitrous oxide emissions from agricultural soils
Nitrous oxide (N2O) is an air pollutant of major environmental concern, with agriculture representing 60% of anthropogenic global N2O emissions. Much of the N2O emissions from livestock production systems result from transformation of N deposited to soil within animal excreta. There exists a substantial body of literature on urine patch N2O dynamics, we aimed to identify key controlling factors influencing N2O emissions and to aid understanding of knowledge gaps to improve GHG reporting and prioritise future research. We conducted an extensive literature review and random effect meta-analysis (using REML) of results to identify key relationships between multiple potential independent factors and global N2O emissions factors (EFs) from urine patches. Mean air temperature, soil pH and ruminant animal species (sheep or cow) were significant factors influencing the EFs reviewed. However, several factors that are known to influence N2O emissions, such as animal diet and urine composition, could not be considered due to the lack of reported data. The review highlighted a widespread tendency for inadequate metadata and uncertainty reporting in the published studies, as well as the limited geographical extent of investigations, which are more often conducted in temperate regions thus far. Therefore, here we give recommendations for factors that are likely to affect the EFs and should be included in all future studies, these include: soil pH and texture; experimental set-up; direct measurement of soil moisture and temperature during the study period; amount and composition of urine applied; animal type and diet; N2O emissions with a measure of uncertainty; data from a control with zero-N application and meteorological data
Remote Estimation of Net Ecosystem CO2 Exchange in Crops: Principles, Technique Calibration and Validation
Accurate and synoptic estimation of spatially distributed CO2 fluxes is of great importance for regional and global studies of carbon balance. A technique solely based on remotely sensed data was developed and tested for estimating net ecosystem CO2 exchange (NEE) in maize and soybean. The model is based on the reflectance in two spectral channels: the near-infrared and either the green or red-edge around 700 nm. The technique provides accurate estimations of mid-day NEE in both crops under either rainfed or irrigated conditions, explaining more than 85% of NEE variation in maize and more than 81% in soybean, and shows great potential for remotely tracking crop NEE
Soil nitrous oxide emissions from grassland: potential inhibitor effect of hippuric acid
In grassland systems, cattle and sheep urine patches are recognized as nitrous oxide (N2O) emission hot spots due to the high urinary nitrogen (N) concentrations. Hippuric acid (HA) is one of the constituents of ruminant urine that has been reported as a natural inhibitor of soil N2O emissions. The aim of this study was to examine the potential for elevated ruminant urine HA concentrations to reduce N2O emissions, in situ, on an acidic heavy clay soil under poorly drained conditions (WFPS > 85%). A randomized complete block design experiment with three replications and four treatments was conducted using the closed-static-flux chamber methodology. The four treatments were applied inside the chambers: control with no artificial urine application (C), control artificial urine (U), and enriched artificial urine containing two rates of HA (55.8 and 90 mM, U+HA1, U+HA2). Soil inorganic-N, soil dissolved organic carbon (DOC), soil pH as well as N2O and methane (CH4) fluxes were monitored over a 79-day period. Although N2O emissions were not affected by the HA enriched urine treatments, U+HA2 positively affected the retention of N as NH4+ until day 3, when the soil pH dropped to values <5. Subsequently, as a consequence of rainfall events and soil acidification, it is likely that leaching or sorption onto clay reduced the efficacy of HA, masking any treatment differential effect on N2O emissions. Moreover, CH4 fluxes as well as DOC results reflected the soil anaerobic conditions which did not favour nitrification processes. Further research is needed to determine the fate of HA into the soil which might clarify the lack of an in situ effect of this compoun
Short-course Benznidazole treatment to reduce Trypanosoma cruzi parasitic load in women of reproductive age (BETTY): A non-inferiority randomized controlled trial study protocol
Background: Retrospective observational studies suggest that transmission of Trypanosoma cruzi does not occur in treated women when pregnant later in life. The level of parasitemia is a known risk factor for congenital transmission. Benznidazole (BZN) is the drug of choice for Preconceptional treatment to reduce parasitic load.The fear of treatment-related side effects limits the implementation of the Argentine guideline recommending BZN 60d/300 mg (or equivalent) treatment of T. cruzi seropositive women during the postpartum period to prevent transmission in a future pregnancy. A short and low dose BZN treatment might reduce major side effects and increase compliance, but its efficacy to reduce T. cruzi parasitic load compared to the standard 60d/300 mg course is not yet established. Clinical trials testing alternative BZN courses among women of reproductive age are urgently needed.Methods and design: We are proposing to perform a double-blinded, non-inferiority randomized controlled trial comparing a short low dose 30-day treatment with BZN 150 mg/day (30d/150 mg) vs. BZN 60d/300 mg. We will recruit not previously treated T. cruzi seropositive women with a live birth during the postpartum period in Argentina, randomize them at 6 months postpartum, and follow them up with the following specific aims:Specific aim 1: to measure the effect of BZN 30d/150 mg compared to 60d/300 mg preconceptional treatment on parasitic load measured by the frequency of positive Polymerase Chain Reaction (PCR) (primary outcome) and by real-time quantitative PCR (qPCR), immediately and 10 months after treatment.Specific aim 2: to measure the frequency of serious adverse events and/or any adverse event leading to treatment interruption.Fil: Cafferata, MarĂa L.. Instituto de Efectividad ClĂnica y Sanitaria; Argentina. Unicem; UruguayFil: Toscani, MarĂa A.. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Althabe, Fernando. Organizacion Mundial de la Salud; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Parque Centenario. Centro de Investigaciones en EpidemiologĂa y Salud PĂșblica. Instituto de Efectividad ClĂnica y Sanitaria. Centro de Investigaciones en EpidemiologĂa y Salud PĂșblica; ArgentinaFil: Belizan, Jose. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Parque Centenario. Centro de Investigaciones en EpidemiologĂa y Salud PĂșblica. Instituto de Efectividad ClĂnica y Sanitaria. Centro de Investigaciones en EpidemiologĂa y Salud PĂșblica; ArgentinaFil: Bergel, Eduardo. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Berrueta, Mabel. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Capparelli, Edmund V.. University of California; Estados UnidosFil: Ciganda, Ălvaro. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Danesi, EmmarĂa. DirecciĂłn Nacional de Institutos de InvestigaciĂłn. AdministraciĂłn Nacional de Laboratorios e Institutos de Salud. Centro Nacional de DiagnĂłstico e Investigaciones Endemo-epidĂ©micas; ArgentinaFil: Dumonteil, Eric. University of Tulane; Estados UnidosFil: Gibbons, Luz. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Gulayin, Pablo ElĂas. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Herrera, Claudia. University of Tulane; Estados UnidosFil: Momper, Jeremiah D.. University of California; Estados UnidosFil: Rossi, Steven. University of California; Estados UnidosFil: Shaffer, Jeffrey G.. University of Tulane; Estados UnidosFil: Schijman, Alejandro Gabriel. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Instituto de Investigaciones en IngenierĂa GenĂ©tica y BiologĂa Molecular "Dr. HĂ©ctor N. Torres"; ArgentinaFil: Sosa-Estani, Sergio Alejandro. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Parque Centenario. Centro de Investigaciones en EpidemiologĂa y Salud PĂșblica. Instituto de Efectividad ClĂnica y Sanitaria. Centro de Investigaciones en EpidemiologĂa y Salud PĂșblica; ArgentinaFil: Stella, Candela B.. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Klein, Karen. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Buekens, Pierre. University of Tulane; Estados Unido
Participant recruitment and retention in longitudinal preconception randomized trials: lessons learnt from the Calcium And Pre-eclampsia (CAP) trial.
BACKGROUND: The preconception period has the potential to influence pregnancy outcomes and randomized controlled trials (RCTs) are needed to evaluate a variety of potentially beneficial preconception interventions. However, RCTs commencing before pregnancy have significant participant recruitment and retention challenges. The Calcium And Pre-eclampsia trial (CAP trial) is a World Health Organization multi-country RCT of calcium supplementation commenced before pregnancy to prevent recurrent pre-eclampsia in which non-pregnant participants are recruited and followed up until childbirth. This sub-study explores recruitment methods and preconception retention of participants of the CAP trial to inform future trials. METHODS: Recruiters at the study sites in Argentina, South Africa and Zimbabwe completed post-recruitment phase questionnaires on recruitment methods used. Qualitative data from these questionnaires and quantitative data on pre-pregnancy trial visit attendance and pregnancy rates up to September 2016 are reported in this paper. RStudio (Version 0.99.903 https://www.rstudio.org ) statistical software was used for summary statistics. RESULTS: Between July 2011 and 8 September 2016, 1354 women with previous pre-eclampsia were recruited. Recruitment took 2Â years longer than expected and was facilitated mainly through medical record/register and maternity ward/clinic-based strategies. Recruiters highlighted difficulties associated with inadequate medical records, redundant patient contact details, and follow-up of temporarily ineligible women as some of the challenges faced. Whilst the attendance rates at pre-pregnancy visits were high (78% or more), visits often occurred later than scheduled. Forty-five percent of participants became pregnant (614/1354), 33.5% (454/1354) within 1Â year of randomization. CONCLUSIONS: In preconception trials, both retrospective and prospective methods are useful for recruiting eligible women with certain conditions. However, these are time-consuming in low-resource settings with suboptimal medical records and other challenges. Trial planners should ensure that trial budgets cover sufficient on-site researchers with pre-trial training, and should consider using mobile phone and web-based electronic tools to optimize recruitment and retention. This should lead to greater efficiency and shorter trial durations. TRIAL REGISTRATION: Pan-African Clinical Trials Registry, Registration Number: PACTR201105000267371 . The trial was registered on 6 December 2016
Maternal and neonatal data collection systems in low- and middle-income countries: Scoping review protocol
Background: Pregnant women and neonates represent one of the most vulnerable groups, especially in low- and middle-income countries (LMICs). A recent analysis reported that most vaccine pharmacovigilance systems in LMICs consist of spontaneous (passive) adverse event reporting. Thus, LMICs need effective active surveillance approaches, such as pregnancy registries. We intend to identify currently active maternal and neonatal data collection systems in LMICs, with the potential to inform active safety electronic surveillance for novel vaccines using standardized definitions. Methods: A scoping review will be conducted based on established methodology. Multiple databases of indexed and grey literature will be searched with a specific focus on existing electronic and paper-electronic systems in LMICs that collect continuous, prospective, and individual-level data from antenatal care, delivery, neonatal care (up to 28 days), and postpartum (up to 42 days) at the facility and community level, at the national and district level, and at large hospitals. Also, experts will be contacted to identify unpublished information on relevant data collection systems. General and specific descriptions of Health Information Systems (HIS) extracted from the different sources will be combined and duplicated HIS will be removed, producing a list of unique statements. We will present a final list of Maternal, Newborn, and Child Health systems considered flexible enough to be updated with necessary improvements to detect, assess and respond to safety concerns during the introduction of vaccines and other maternal health interventions. Selected experts will participate in an in-person consultation meeting to select up to three systems to be further explored in situ. Results and knowledge gaps will be synthesized after expert consultation.Fil: Berrueta, Mabel. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Bardach, Ariel Esteban. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Parque Centenario. Centro de Investigaciones en EpidemiologĂa y Salud PĂșblica. Instituto de Efectividad ClĂnica y Sanitaria. Centro de Investigaciones en EpidemiologĂa y Salud PĂșblica; ArgentinaFil: Ciapponi, AgustĂn. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Oficina de CoordinaciĂłn Administrativa Parque Centenario. Centro de Investigaciones en EpidemiologĂa y Salud PĂșblica. Instituto de Efectividad ClĂnica y Sanitaria. Centro de Investigaciones en EpidemiologĂa y Salud PĂșblica; ArgentinaFil: Xiong, Xu. University of Tulane; Estados UnidosFil: Stergachis, Andy. University of Washington; Estados UnidosFil: Zaraa, Sabra. University of Washington; Estados UnidosFil: Buekens, Pierre. University of Tulane; Estados UnidosFil: Absalon, Judith. No especifĂca;Fil: Anderson, Steve. No especifĂca;Fil: Althabe, Fernando. Instituto de Efectividad ClĂnica y Sanitaria; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Madhi, Shabir A.. No especifĂca;Fil: McClure, Elizabeth. No especifĂca;Fil: Munoz, Flor M.. No especifĂca;Fil: Mwamwitwa, Kissa W.. No especifĂca;Fil: Nakimuli, Annettee. No especifĂca;Fil: Clark Nelson, Jennifer. No especifĂca;Fil: Noguchi, Lisa. No especifĂca;Fil: Panagiotakopoulos, Lakshmi. No especifĂca;Fil: Sevene, Esperanca. No especifĂca;Fil: Zuber, Patrick. No especifĂca;Fil: Belizan, Maria. No especifĂca;Fil: Bergel, Eduardo. No especifĂca;Fil: Rodriguez Cairoli, Federico. No especifĂca;Fil: Castellanos, Fabricio. No especifĂca;Fil: Ciganda, Alvaro. No especifĂca;Fil: Comande, Daniel. No especifĂca;Fil: Pingray, Veronica. No especifĂca
A multifaceted intervention to improve syphilis screening and treatment in pregnant women in Kinshasa, Democratic Republic of the Congo and in Lusaka, Zambia: a cluster randomised controlled trial
Background: Despite international recommendations, coverage of syphilis testing in pregnant women and treatment of those found seropositive remains limited in sub-Saharan Africa. We assessed whether combining the provision of supplies with a behavioural intervention was more effective than providing supplies only, to improve syphilis screening and treatment during antenatal care. Methods: In this 18-month, cluster randomised controlled trial, we randomly assigned (1:1) 26 urban antenatal care clinics in Kinshasa, Democratic Republic of the Congo, and Lusaka, Zambia, to receive a behavioural intervention (opinion leader selection, academic detailing visits, reminders, audits and feedback, and supportive supervision) plus supplies for syphilis testing and treatment (intervention group) or to receive supplies only (control group). The primary outcomes were proportion of pregnant women who had syphilis screening out of the total who attended the clinic; and the proportion of women who had treatment with benzathine benzylpenicillin out of those who tested positive for syphilis at their first antenatal care visit. This trial is registered at ClinicalTrials.gov, number NCT02353117. Findings: The 18-month study period was Feb 1, 2016, to July 14, 2017. 18 357 women were enrolled at the 13 intervention clinics and 17 679 women were enrolled at the 13 control clinics at their first antenatal care visit. Syphilis screening was done in a median of 99·9% (IQR 99·0â100·0) of women in the intervention clinics and 93·8% (85·0â98·9) in the control clinics (absolute difference 6·1% [95% CI 1·1â14·1]; p=0·00092). Syphilis treatment at the first visit was done in a median of 100% (IQR 99·7â100·0) of seropositive women in intervention clinics and 43·2% (2·6â83·2) of seropositive women in control clinics (absolute difference 56·8% [12·8â99·0]; p=0·0028). Interpretation: A behavioural intervention, together with the provision of supplies, can lead to more than 95% of women being screened and treated for syphilis. The sole provision of supplies is sufficient to reach such levels of screening coverage but is not sufficient to ensure high levels of treatment. Funding: Bill & Melinda Gates Foundation.Fil: Althabe, Fernando. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; Argentina. Instituto de Efectividad ClĂnica y Sanitaria; Argentina. Organizacion Mundial de la Salud; ArgentinaFil: Chomba, Elwyn. University Teaching Hospital of Lusaka; ZambiaFil: Tshefu, Antoinette K. University of Kinshasa; RepĂșblica DemocrĂĄtica del CongoFil: Banda, Ernest. University Teaching Hospital of Lusaka; ZambiaFil: BelizĂĄn, MarĂa Melina Eleonora. Instituto de Efectividad ClĂnica y Sanitaria; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Bergel, Eduardo. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Berrueta, Amanda Mabel. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Bertrand, Jane. University of Tulane; Estados UnidosFil: Bose, Carl. University of North Carolina; Estados UnidosFil: Cafferata, Maria Luisa. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Carlo, Waldemar A. University of Alabama at Birmingahm; Estados UnidosFil: Ciganda, Alvaro. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Donnay, France. University of Tulane; Estados UnidosFil: Garcia Elorrio, Ezequiel. Instituto de Efectividad ClĂnica y Sanitaria; Argentina. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas; ArgentinaFil: Gibbons, Luz. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Klein, Karen. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Liljestrand, Jerker. Bill And Melinda Gates Foundation; Estados UnidosFil: Lusamba, Paul D. University of Kinshasa; RepĂșblica DemocrĂĄtica del CongoFil: Mavila, Arlette K. University of Kinshasa; RepĂșblica DemocrĂĄtica del CongoFil: Mazzoni, Agustina. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Nkamba, Dalau M. University of Kinshasa; RepĂșblica DemocrĂĄtica del CongoFil: Mwanakalanga, Friday H. University Teaching Hospital Lusaka; ZambiaFil: Mwapule Tembo, Abigail. University Teaching Hospital Lusaka; ZambiaFil: Mwenechanya, Musaku. University Teaching Hospital Lusaka; ZambiaFil: Pyne Mercier, Lee. Bill And Melinda Gates Foundation; Estados UnidosFil: Spira, Cintia. Instituto de Efectividad ClĂnica y Sanitaria; ArgentinaFil: Wetshikoy, Jean D. University of Kinshasa; RepĂșblica DemocrĂĄtica del CongoFil: Xiong, Xu. University of Tulane; Estados UnidosFil: Buekens, Pierre. University of Tulane; Estados Unido
Dietary supplements and herbal medicine toxicitiesâwhen to anticipate them and how to manage them
Prepregnancy and early pregnancy calcium supplementation among women at high risk of pre-eclampsia : a multicentre, double-blind, randomised, placebo-controlled trial
CITATION: Hofmeyr, G. J., et al. 2019. Prepregnancy and early pregnancy calcium supplementation among women at high risk of pre-eclampsia : a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet, 393(10169):P330-339, doi:10.1016/S0140-6736(18)31818-X.The original publication is available at https://www.thelancet.comBackground: Reducing deaths from hypertensive disorders of pregnancy is a global priority. Low dietary calcium
might account for the high prevalence of pre-eclampsia and eclampsia in low-income countries. Calcium
supplementation in the second half of pregnancy is known to reduce the serious consequences of pre-eclampsia;
however, the effect of calcium supplementation during placentation is not known. We aimed to test the hypothesis
that calcium supplementation before and in early pregnancy (up to 20 weeksâ gestation) prevents the development
of pre-eclampsia
Methods: We did a multicountry, parallel arm, double-blind, randomised, placebo-controlled trial in South Africa,
Zimbabwe, and Argentina. Participants with previous pre-eclampsia and eclampsia received 500 mg calcium or
placebo daily from enrolment prepregnancy until 20 weeksâ gestation. Participants were parous women whose most
recent pregnancy had been complicated by pre-eclampsia or eclampsia and who were intending to become pregnant.
All participants received unblinded calcium 1·5 g daily after 20 weeksâ gestation. The allocation sequence (1:1 ratio)
used computer-generated random numbers in balanced blocks of variable size. The primary outcome was
pre-eclampsia, defined as gestational hypertension and proteinuria. The trial is registered with the Pan-African
Clinical Trials Registry, number PACTR201105000267371. The trial closed on Oct 31, 2017.
Findings: Between July 12, 2011, and Sept 8, 2016, we randomly allocated 1355 women to receive calcium or placebo;
331 of 678 participants in the calcium group versus 320 of 677 in the placebo group became pregnant, and 298 of
678 versus 283 of 677 had pregnancies beyond 20 weeksâ gestation. Pre-eclampsia occurred in 69 (23%) of
296 participants in the calcium group versus 82 (29%) of 283 participants in the placebo group with pregnancies
beyond 20 weeksâ gestation (risk ratio [RR] 0·80, 95% CI 0·61â1·06; p=0·121). For participants with compliance
of more than 80% from the last visit before pregnancy to 20 weeksâ gestation, the pre-eclampsia risk was 30 (21%)
of 144 versus 47 (32%) of 149 (RR 0·66, CI 0·44â0·98; p=0·037). There were no serious adverse effects of
calcium reported.
Interpretation: Calcium supplementation that commenced before pregnancy until 20 weeksâ gestation, compared with
placebo, did not show a significant reduction in recurrent pre-eclampsia. As the trial was powered to detect a large
effect size, we cannot rule out a small to moderate effect of this intervention.
ernal and Child Health.https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31818-X/fulltextPublisher's versio
- âŠ